Grootendorst, Paul - Department of Economics, McMaster University - 2007
generic competitors should lower prices. On the other hand, the threat of AG entry into a therapeutic market might deter entry … of AG entry into a market might deter entry by IGs. IG executives, however, state that the threat of AG entry has … decreased their incentive to challenge ‘marginal’ drug markets. In particular the threat of AG entry has increased from $5m to …
